Literature DB >> 22826720

Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma.

Kamer Gündüz1, Umran Günay, Işıl Inanir, Gülsüm Gençoğlan, Peyker Temiz.   

Abstract

BACKGROUND: The classic Kaposi sarcoma is most common in the Mediterranean population over 50 years of age and presents with reddish-brown papules and nodules particularly on the lower limbs. Treatment depends on the clinical presentation and extension of lesions. Imiquimod is as an immune response modifier with antiangiogenic activity. MAIN OBSERVATIONS: We present a 74-year-old man with classic Kaposi sarcoma who had multiple, small, violaceous papules and nodules on the trunk and extremities with a history of 14 years. He complained particularly from plantar hyperkeratotic painful nodules. Treatment with imiquimod 5% cream under occlusion resulted with almost complete regression within 12 weeks. No local or systemic side effects were observed.
CONCLUSIONS: Topical imiquimod was a safe and effective therapy in our patient with classic Kaposi sarcoma.

Entities:  

Keywords:  Kaposi sarcoma; imiquimod; skin cancer; treatment

Year:  2012        PMID: 22826720      PMCID: PMC3399677          DOI: 10.3315/jdcr.2012.1099

Source DB:  PubMed          Journal:  J Dermatol Case Rep        ISSN: 1898-7249


  9 in total

1.  Imiquimod for the treatment of classical Kaposi's sarcoma.

Authors:  Bianca Bernardini; Diana Faggion; Luisella Calabró; Elisabetta Oro; Mauro Alaibac
Journal:  Acta Derm Venereol       Date:  2010-07       Impact factor: 4.437

2.  Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients.

Authors:  Noël Emile Célestin Schartz; Sylvie Chevret; Carolina Paz; Delphine Kerob; Olivier Verola; Patrice Morel; Céleste Lebbé
Journal:  J Am Acad Dermatol       Date:  2008-02-20       Impact factor: 11.527

3.  Treatment of classic Kaposi's sarcoma with topical imiquimod.

Authors:  Rebeca Goiriz; Luis Ríos-Buceta; Ana González De Arriba; Maximiliano Aragüés; Amaro García-Diez
Journal:  Dermatol Surg       Date:  2008-12-06       Impact factor: 3.398

4.  [Clinical remission of classic Kaposi sarcoma with topical 5% imiquimod].

Authors:  B Echeverría-García; O Sanmartín; C Guillén
Journal:  Actas Dermosifiliogr       Date:  2010-03

5.  Eruptive Kaposi sarcoma: an unusual presentation in an HIV-negative patient.

Authors:  Mollie M Jan; Joseph W Laskas; Thomas D Griffin
Journal:  Cutis       Date:  2011-01

6.  Pyogenic granuloma in children: treatment with topical imiquimod.

Authors:  Haady Fallah; Gayle Fischer; Samuel Zagarella
Journal:  Australas J Dermatol       Date:  2007-11       Impact factor: 2.875

Review 7.  Antiangiogenesis in the treatment of skin cancer.

Authors:  Vincent W Li; William W Li
Journal:  J Drugs Dermatol       Date:  2008-01       Impact factor: 2.114

8.  Pyogenic granuloma in two children successfully treated with imiquimod 5% cream.

Authors:  Gulsum Gencoglan; Isil Inanir; Kamer Gündüz
Journal:  Pediatr Dermatol       Date:  2009 May-Jun       Impact factor: 1.588

Review 9.  Management of cutaneous hemangiomas in pediatric patients.

Authors:  Maria Letizia Musumeci; Karina Schlecht; Rosario Perrotta; Robert A Schwartz; Giuseppe Micali
Journal:  Cutis       Date:  2008-04
  9 in total
  3 in total

Review 1.  HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Authors:  Khatiya Chelidze; Cristina Thomas; Aileen Yenting Chang; Esther Ellen Freeman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

2.  Topical treatments for Kaposi sarcoma: A systematic review.

Authors:  Kyaw Zin Htet; Michael Andrew Waul; Kieron Seymour Leslie
Journal:  Skin Health Dis       Date:  2022-04-08

Review 3.  Imiquimod - Its role in the treatment of cutaneous malignancies.

Authors:  Aditya Kumar Bubna
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.